Last reviewed · How we verify

Epidural analgesia Ropivacaine

Universitair Ziekenhuis Brussel · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. Used for Epidural analgesia for postoperative pain management, Epidural anesthesia for surgical procedures.

At a glance

Generic nameEpidural analgesia Ropivacaine
SponsorUniversitair Ziekenhuis Brussel
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes. This prevents sodium influx and depolarization, thereby inhibiting nerve impulse conduction. When administered epidurally, it produces localized anesthesia and analgesia in the distribution of the spinal nerves.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: